Compile Data Set for Download or QSAR
Report error Found 705 Enz. Inhib. hit(s) with all data for entry = 12168
TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684451(US20240218021, Example 669)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684390(US20240218021, Example 638)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684322(US20240218021, Example 257)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684066(US20240218021, Example 129)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Spiny starfish)
Circle Pharma

US Patent
LigandPNGBDBM683991(US20240218021, Example 438)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684206(US20240218021, Example 199)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM683885(US20240218021, Example 385)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684271(US20240218021, Example 578)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684499(US20240218021, Example 693)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684374(US20240218021, Example 630)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684437(US20240218021, Example 662)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Spiny starfish)
Circle Pharma

US Patent
LigandPNGBDBM684220(US20240218021, Example 206)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM683985(US20240218021, Example 435)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684497(US20240218021, Example 692)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM683987(US20240218021, Example 436)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Spiny starfish)
Circle Pharma

US Patent
LigandPNGBDBM684472(US20240218021, Example 333)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Spiny starfish)
Circle Pharma

US Patent
LigandPNGBDBM683811(US20240218021, Example 348)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684313(US20240218021, Example 599)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684376(US20240218021, Example 631)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Spiny starfish)
Circle Pharma

US Patent
LigandPNGBDBM684383(US20240218021, Example 288)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684315(US20240218021, Example 600)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684378(US20240218021, Example 632)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 1/G2/mitotic-specific cyclin-B(Spiny starfish)
Circle Pharma

US Patent
LigandPNGBDBM684468(US20240218021, Example 331)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684483(US20240218021, Example 685)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684040(US20240218021, Example 116)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684479(US20240218021, Example 683)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684492(US20240218021, Example 343)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684491(US20240218021, Example 689)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684493(US20240218021, Example 690)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM683983(US20240218021, Example 434)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684360(US20240218021, Example 623)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM683979(US20240218021, Example 432)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684467(US20240218021, Example 677)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684465(US20240218021, Example 676)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684412(US20240218021, Example 303)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684351(US20240218021, Example 618)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684471(US20240218021, Example 679)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684347(US20240218021, Example 616)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684155(US20240218021, Example 520)
Affinity DataIC50: 20nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684388(US20240218021, Example 637)
Affinity DataIC50: 30nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684258(US20240218021, Example 225)
Affinity DataIC50: 30nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684003(US20240218021, Example 444)
Affinity DataIC50: 30nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684067(US20240218021, Example 476)
Affinity DataIC50: 30nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684074(US20240218021, Example 133)
Affinity DataIC50: 30nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684012(US20240218021, Example 102)
Affinity DataIC50: 30nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684307(US20240218021, Example 596)
Affinity DataIC50: 30nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684364(US20240218021, Example 625 | US20240218021, Exampl...)
Affinity DataIC50: 30nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684062(US20240218021, Example 127)
Affinity DataIC50: 30nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM684064(US20240218021, Example 128)
Affinity DataIC50: 30nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

TargetCyclin-A2/Cyclin-dependent kinase 2(Human)
Circle Pharma

US Patent
LigandPNGBDBM683999(US20240218021, Example 442)
Affinity DataIC50: 30nMAssay Description:FP binding assays were performed in 25 mM HEPES pH 7.5, 100 mM NaCl, 1 mM DTT, 0.01% NP-40 and 1 mg/mL BSA for all 3 protein complexes in black 96-we...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/12/2024
Entry Details
US Patent

Displayed 1 to 50 (of 705 total ) | Next | Last >>
Jump to: